Nrx pharmaceuticals (nasdaq:nrxp) reports preliminary fourth quarter and full year 2023 financial results and provides year end highlights

Four potential near-term milestones, including data from two clinical trials, an nda filing and a share dividend radnor, pa. , march 28, 2024 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage biopharmaceutical company, today announces its anticipated financial results for the quarter and year ended december 31, 2023 and provides the following summary of its expected annual report to be filed later today.
NRXP Ratings Summary
NRXP Quant Ranking